SpainSpain

Bone Repair Studies Started

13.11.2004

Barcelona/Ann Arbor - US Aastrom Biosciences, Inc. and the Institut de Terapia Regenerativa Tissular (ITRT) announced in October that they will expand a bone graft study based on initial results from the first phase of patient treatments. The trial involved five patient treatments using Aastrom's Tissue Repair Cells (TRCs) for the bone graft repair of severe long bone non-union fractures, and was completed at the Hospital General de l'Hospitalet, Centro Medico Teknon and Hospital de Barcelona-SCIAS.
This trial was initiated in March 2004 in co-operation with ITRT who coordinated the trial implementation. The study was designed to evaluate the safety and effectiveness of TRCs to regenerate new, healthy bone in the repair of long bone non-union fractures. All of the patients who received TRC treatment had pre-viously failed to repair their fractures using standard procedures.

SpainSpain

08.06.2010

Barcelona/Triangle Park – Spanish producer of plasma protein therapies Grifols is to acquire US public biopharmaceutical company Talecris, in a deal worth approximately $3.4 billion (EUR2.8 billion). The merger will improve...

SpainSpain

12.05.2010

Madrid – In the last few years, the number of companies interested in mining marine life for interesting substances has risen steadily. Madrid-based Pharmamar was one of the first, and is also one of the very few to have a...

SpainSpain

11.05.2010

Pamplona – From Sept. 29th-Oct. 1st, Pamplona will become the centre of the European biotechnology world when the city famous for the annual running of the bulls through the medieval town centre hosts the BioSpain 2010. The...

SpainSpain

07.03.2010

San Sebastian – Europe has to unify its research efforts and infrastructures if it doesn’t want to be overtaken by Asian competitors such as China in the mid-term – that was Spanish Science Minister Cristina Garmendia’s message...

SpainSpain

07.03.2010

Madrid/Rockville – Spain’s Rovi Pharmaceuticals has terminated talks with US vaccine specialist Novavax Inc. to license recombinant virus-like particle (VLP) vaccine technology to help Spain meet its seasonal and pandemic flu...

SpainSpain

01.02.2010

Barcelona – Ferrer inCode has agreed to distribute DiaGenic’s blood-based ADtect test for the early diagnosis of Alzheimer’s Disease. The agreement with the Oslo-based company gives Ferrer inCode, a biotech subsidiary of Grupo...

SpainSpain

01.02.2010

Seville – Scientists at the University of Seville have published the first demographic map of colon cancer in Spain. The analysis examines Spanish trends between 1951-2006 in terms of particular changes in consumption patterns...

SpainSpain

01.02.2010

Madrid – A goundbreaking technique that promised to speed up the discovery of novel microbial enzymes from environmental samples has come in for criticism. Soon after scientists from Spain, Germany, and the UK had presented their...

SpainSpain

27.11.2009

Barcelona/Heidelberg – US genome pioneer Craig Venters’ plan to create a minimal synthetic cell based on the essential genes of Mycoplasma bacteria may ultimately be too ambitious. A brand new study conducted by a team of...

Displaying results 31 to 40 out of 181

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-spain/browse/3/article/bone-repair-studies-started.html

Events

All Events

Stock list

All quotes

TOP

  • NOVACYT (F)4.98 EUR5.96%
  • STALLERGENES (F)53.50 EUR4.37%
  • MORPHOSYS (D)72.25 EUR3.96%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • OREXO (S)137.00 SEK-5.35%

TOP

  • WILEX (D)3.10 EUR307.9%
  • SANTHERA (CH)67.95 CHF88.7%
  • ADDEX (CH)4.03 CHF79.9%

FLOP

  • MERCK KGAA (D)64.38 EUR-49.4%
  • HYBRIGENICS (F)1.77 EUR-27.5%
  • CHRONTECH PHARMA (S)0.07 SEK-22.2%

TOP

  • SANTHERA (CH)67.95 CHF3297.5%
  • GW PHARMACEUTICALS (UK)419.75 GBP642.9%
  • PAION (D)2.77 EUR319.7%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • THROMBOGENICS (B)9.54 EUR-69.4%

No liability assumed, Date: 28.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products